In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...

FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has secured a US notice of allowance for a continuation patent covering its ...

A Guildford-based developer of sexual health products, including erectile dysfunction treatment Eroxon, has reported strong trading in a new update.

Luke Miels' first financial results since taking over as chief executive of GSK revealed a jump in sales and profits, fuelled ...

TrumpRx is aimed at helping patients use their own money to buy medicines. But researchers who study drug pricing warned that ...

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript February 3, 2026 Operator: Good day, everyone. And ...

Biotech Stocks to Watch as Obesity Market Expands Expert highlights domestic pharma opportunities as Wegovy patent nears, ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

Polaryx believes the addition of Dr. Berger, Mr. Braun, and Dr. Ryan brings valuable expertise across scientific research, ...

According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as LB-P8 ...